
    
      This will be a multi-center, open labeled, randomized comparative trial Patients: 240
      patients with H. pylori infection who failed after first-line therapy will be eligible

      Interventions: eligible patients will be randomized into one of the two groups Group (A):
      sequential therapy for 14 days (S14)

      D1-D7: (esomeprazole 40mg bid + amoxicillin 1000mg bid) for 7 days

      D8-D14: (esomeprazole 40mg bid + clarithromycin 500mg bid + metronidazole 500mg bid) for
      another 7 days

      Group (B): bismuth quadruple therapy for 10 days (Q10)

      D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid +
      tetracycline 500mg qid) for 10 days

      Primary End Point: Eradication rate in the second line treatment according to intention to
      treat (ITT) analysis in the two treatment groups
    
  